pd 183805 (ci 1033, 2-propenamide, n-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-, dihydrochloride (Pfizer Inc)
90
Structured Review
Pfizer Inc
pd 183805 (ci 1033, 2-propenamide, n-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-, dihydrochloride
Pd 183805 (Ci 1033, 2 Propenamide, N [4 [(3 Chloro 4 Fluorophenyl)amino] 7 [3 (4 Morpholinyl)propoxy] 6 Quinazolinyl] , Dihydrochloride, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ci-1033/ci+1033/us12251383-452-18-19
Average 90 stars, based on 1 article reviews
Pd 183805 (Ci 1033, 2 Propenamide, N [4 [(3 Chloro 4 Fluorophenyl)amino] 7 [3 (4 Morpholinyl)propoxy] 6 Quinazolinyl] , Dihydrochloride, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ci-1033/ci+1033/us12251383-452-18-19
Average 90 stars, based on 1 article reviews
pd 183805 (ci 1033, 2-propenamide, n-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-, dihydrochloride - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Binding Assay:Article Title: Agents and methods for predicting response to therapy Article Snippet: No. 5,804,396); Article Title: Condensed tricyclic compounds as protein kinase inhibitors Article Snippet: No. 5,804,396); Article Title: Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer Article Snippet: No. 5,804,396); Article Title: Multivalent and monovalent multispecific complexes and their uses Article Snippet: In an additional embodiment, an ErbB2 (HER2) binding MRD-containing antibody is administered in combination with a protein kinase inhibitor selected from: canertinib (GW-572016), AV-412 (AVEO), tivozanib (AVEO), vandetanib (e.g., ZACTIMATM, AstraZeneca), AEE788 (Novartis), Exel 7646/Exel 0999 (Exelixis), Article Title: Multivalent and monovalent multispecific complexes and their uses Article Snippet: In another embodiment, an EGFR binding MRD-containing antibody is administered in combination with a protein kinase inhibitor selected from: canertinib (GW-572016), ZD6474, AV-412 (AVEO), tivozanib (AVEO), vandetanib (ZACTIMA, AstraZeneca), AEE788 (Novartis), Exel 7646/Exel 0999 (Exelixis), Article Title: Cancer Metabolism: Current Understanding and Therapies. Article Snippet: Dysregulation of cancer cell metabolism contributes to abnormal cell growth, the biological end point of cancer.. We review here numerous affected oncogenes and metabolic pathways common in cancer and how they contribute to cancer pathogenesis and malignancy.. This review also discusses various pharmacological manipulations that take advantage of these metabolic abnormalities and the current targeted therapies that have arisen from this research. Article Title: Method for detecting protein modifications using specific antibodies Article Snippet: Two such inhibitors are in advanced stage of Article Title: Multivalent and monovalent multispecific complexes and their uses Article Snippet: In a specific embodiment a trastuzumab antibody-based MRD-containing antibody is administered in combination with a protein kinase inhibitor selected from: canertinib (GW-572016), AV-412 (AVEO), tivozanib (AVEO), vandetanib (e.g., ZACTIMATM, AstraZeneca), AEE788 (Novartis), Exel 7646/Exel 0999 (Exelixis), |
